Table 5.
Association between management and percentage of successfully managed AlP-intoxicated patients (n = 80)a.
| Survived cases | Sig. | ||||
|---|---|---|---|---|---|
| n = 50 | ≤20% | n = 30 | ≥30% | ||
| 1. Personal and professional data of participants | |||||
| Age | |||||
| 25 to <30 | 22 | 44.0 | 13 | 43.3 | .954 |
| ≥30 | 28 | 56.0 | 17 | 56.7 | |
| Specialty | |||||
| Clinical toxicologist | 22 | 44.0 | 21 | 70.0 | .024b |
| Other specialties | 28 | 56.0 | 9 | 30.0 | |
| Years of experience | |||||
| <5 | 21 | 42.0 | 15 | 50.0 | .486 |
| ≥5 | 29 | 58.0 | 15 | 50.0 | |
| Academic degree | |||||
| Bachelor | 15 | 30.0 | 11 | 36.7 | .537 |
| Master | 23 | 46.0 | 10 | 33.3 | |
| Doctorate | 12 | 24.0 | 9 | 30.0 | |
| Job description | |||||
| Resident/demonstrator | 19 | 38.0 | 17 | 56.7 | 0.098 |
| Specialist | 22 | 44.0 | 6 | 20.0 | |
| Consultant | 9 | 18.0 | 7 | 23.3 | |
| Affiliated institute | |||||
| University hospitals | 39 | 78.0 | 27 | 90.0 | 0.171 |
| Other healthcare institutes | 11 | 22.0 | 3 | 10.0 | |
| 2. CVS supportive measures | |||||
| Fluid therapyc | |||||
| Initiated Empirically IV Crystalloids | 30 | 60.0 | 18 | 60.0 | 1 |
| Guided with CVP measurement | 19 | 38.0 | 17 | 56.7 | 0.104 |
| Guided with ECHO | 20 | 40.8 | 9 | 30.0 | 0.333 |
| Management of ALP-induced refractory hypotensionc | |||||
| Noradrenaline | 47 | 94.0 | 25 | 83.3 | 0.144 |
| Dobutamine and/or dopamine | 20 | 40.8 | 17 | 56.7 | 0.171 |
| IV Hydrocortisone | 11 | 22.0 | 7 | 23.3 | 0.890 |
| Aggressive CVS supportive measures | 7 | 14.0 | 5 | 16.7 | 0.756 |
| Noradrenaline infusion dose regimen isc | |||||
| No fixed regimen for noradrenaline infusion in these cases. | 17 | 34.0 | 9 | 30.0 | 0.712 |
| Start with rate of infusion 5 ml/h of single dose | 15 | 30.0 | 10 | 33.3 | 0.755 |
| Start with rate of infusion 7.4 ml/h of single dose | 2 | 4.0 | 3 | 10.0 | 0.358 |
| Dose readjusted every 30 min or 1 h according to perfusion status. | 29 | 58.0 | 13 | 43.3 | 0.203 |
| Maximum rate of infusion (≥30 ml/h single dose) applied in severe cases. | 14 | 28.0 | 8 | 26.7 | 0.897 |
| 3. GIT decontamination | |||||
| GIT decontamination that you do to manage acute AlP poisoning include | |||||
| No decontamination | 1 | 2.0 | 2 | 6.7 | 0.015b |
| Oil | 40 | 80.0 | 28 | 93.3 | |
| Aqueous | 9 | 18.0 | 0 | 0.0 | |
| 4. Other supportive measures | |||||
| Supportive measuresc | |||||
| Sodium bicarbonate infusion | 44 | 88.0 | 27 | 90.0 | 1 |
| IV Magnesium sulfate | 19 | 38.0 | 16 | 53.3 | 0.181 |
| Prophylactic anti-arrhythmic, e.g. amiodarone | 3 | 6.0 | 5 | 16.7 | 0.144 |
| IV lipid emulsion | 5 | 10.0 | 1 | 3.3 | 0.402 |
| Antioxidant therapy | 15 | 30.0 | 12 | 40.0 | 0.360 |
| Proton pump inhibitor | 31 | 62.0 | 22 | 73.3 | 0.299 |
| Sodium bicarbonate infusion (1 mEq/kg) regimen | |||||
| Empirically initiated before calculation of base deficit. | 20 | 40.0 | 11 | 36.7 | 0.767 |
| Initiated following calculation of base deficit. | 30 | 60.0 | 19 | 63.3 | |
ECHO, echocardiogram.
aIn all, 71 participants (47%) could not determine the percentage of successfully managed cases.
bSignificant results ≤ 0.05
cMultiple response question.